GeneDx Swings to Profit, Secures $55M Blackstone Financing
WGS sits 94% above its 52-week low of $32.21.
Summary
GeneDx posted Q2 2026 revenue of $114.4 million, grew exome/genome volume 32%, and reached adjusted net income of $0.4 million. Full-year guidance was reaffirmed, and a $55 million financing package from Blackstone—comprising a $50 million term loan and a $5 million equity investment at $61.00 per share—was announced.
Key Events · Earnings and Guidance · WGS
-
Q2 Revenue and Volume Beat
Revenue reached $114.4 million, with exome and genome test revenue of $100.3 million (up 17% YoY) on volume of 30,785 tests (up 32% YoY).
-
Return to Profitability
Adjusted net income was $0.4 million, a $8.6 million improvement from Q1 2026, driven by 70% adjusted gross margin and operating expense discipline.
-
Guidance Reaffirmed and Q3 Targets Set
Full-year 2026 revenue guidance of $475-$490 million reiterated; Q3 2026 revenue expected at $122-$124 million with adjusted net income of approximately $2 million.
-
Blackstone Financing Strengthens Balance Sheet
Amended loan agreement adds $50 million term loan (total facility $150 million) and a $5 million equity private placement at $61.00 per share, bringing pro forma cash to ~$188 million.
Analysis · WGS · Industrial Applications And Services
A strong second quarter saw GeneDx deliver $114.4 million in revenue and a 32% year-over-year jump in exome/genome volume, flipping to adjusted net income of $0.4 million after a deep first-quarter loss. Confidence in the trajectory is underscored by reaffirmed full-year guidance and newly issued third-quarter targets. At the same time, the company expanded its term loan by $50 million and placed $5 million in equity with Blackstone at $61.00 per share—a premium to the recent stock price—lifting pro forma cash to roughly $188 million. The transaction eliminates near-term liquidity risk and validates the business model with a sophisticated life sciences investor, though the equity placement brings modest dilution.
At the time of this filing, WGS was trading at $62.47 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $32.21 to $170.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.